Lung cancer remains the most lethal cancer in the world. Gain-of-function mutations in K-ras are found in 25% to 40% of lung cancers and are thought to be significant drivers of oncologic virulence. There are currently no targeted therapies that effectively treat K-ras mutant lung tumors. In fact, these mutations are characterized by their resistance to epidermal growth factor receptor (EGFR) inhibitors. 1, 2 Phospholipase A 2 (PLA 2 ) enzymes release arachidonic acid from cell membranes, initiating downstream production of tumor-promoting eicosanoids. Group IIa secretory phospholipase A 2 (sPLA 2 IIa), a subgroup of PLA 2 s, has recently been identified as a potential lung cancer biomarker. 3 In a cohort of patients with solitary pulmonary nodules, patients with lung cancer had higher plasma levels of sPLA 2 IIa than patients with a benign nodule. In addition, histologic analysis demonstrates overexpression of sPLA 2 IIa in lung tumors compared with normal lung tissue. 3 From a functional perspective, sPLA 2 IIa has been shown to regulate lung cancer cell growth and invasion. RNA interference of sPLA 2 IIa decreases tumor growth and nuclear factor kappa-b (NF-kB) activity in a xenograft model of lung cancer. 4 In addition, sPLA 2 IIa inhibition decreases intercellular adhesion molecule-1-associated invasion in vitro. 5 Although cytosolic PLA 2 activity is increased in K-ras mutant lung tumors, [6] [7] [8] the relationship between sPLA 2 IIa and K-ras mutant lung cancer has not previously been explored. The aim of this study is to examine the potential of targeted sPLA 2 IIa inhibition in K-ras mutant lung cancer. Our purpose was twofold: (1) to investigate the role of sPLA 2 IIa in the growth of K-ras mutant lung cancer cells and (2) to examine sPLA 2 IIa expression in human tumor specimens and correlate the results with K-ras mutation status. We hypothesized that sPLA 2 IIa modulates lung cancer cell growth in K-ras mutant cells and that tumor expression of sPLA 2 IIa would correlate with K-ras status and cancer stage.
METHODS

Cells and Reagents
All cell lines tested were K-ras mutant derived from non-small cell lung cancers (Table 1) . A549 cells were a gift from Dr Anirban Banerjee (Aurora, Colo). H358 cells were a gift from Dr Kim O'Neill (Provo, Utah). SW1573 and H2009 were a gift from Dr Mary Reyland (Aurora, Colo). Cells were maintained in a humidified atmosphere with 5% carbon dioxide using Ham's F-12 (A549) or RPMI media (all other cell lines) with 10% fetal bovine serum (FBS). Tumor necrosis factor-alpha (TNF-a) (Sigma-Aldrich, St Louis, Mo) was used at a concentration of 20 ng/mL to mimic the inflammatory milieu of the tumor microenvironment. The sPLA 2 IIa inhibitor S3319 (Sigma Aldrich) was dissolved in dimethyl sulfoxide. Dimethyl sulfoxide served as a vehicle control for all experiments with a maximum experimental concentration of 0.08%. Rabbit anti-human antibodies for phosphorylated and total NF-kB p65, extracellular signalregulated kinase (ERK) 1/2, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were obtained from Cell Signaling Technology, Inc (Beverly, Mass). For Western blot, the rabbit anti-human-specific sPLA 2 IIa antibody was from Abcam (Cambridge, Mass). For immunofluorescence, the rabbit anti-human sPLA 2 IIa antibody was obtained from BioVendor, LLC (Candler, NC).
Immunofluorescence Microscopy
We cultured 5000 cells per chamber on Lab-Tek II 8-well glass chamber slides (Thermo Scientific, Rochester, NY) in full media for 24 hours and then serum-starved them (0.5% FBS) for 24 hours. Cells were pretreated with incrementally increasing concentrations of the sPLA 2 inhibitor in serum-starved media for 1 hour, then stimulated with 20 ng/mL TNF-a for 8 hours. Control cells were incubated with dimethyl sulfoxide in serum-starved media and stimulated with TNF-a for 8 hours. Immunofluorescence microscopy was performed to evaluate sPLA 2 IIa expression in A549 cells as previously described. 9
Apoptosis Assay
We cultured 1 3 10 6 cells per well in 12-well plates in full media for 24 hours and then serum-starved them (0.5% FBS) for 24 hours before treatment. Cells were treated with sPLA 2 IIa inhibitor (20 or 40 mmol/L) or vehicle control in serum-starved media for 8 hours. A time-response experiment using 4-and 8-hour time points was used to determine the 8-hour time point chosen for this experiment (data not shown). Apoptosis was assessed by flow cytometric detection of annexin V and propidium iodide (BD Biosciences, San Jose, Calif).
Cell Viability Assay
We cultured 5 3 10 3 cells per well in 96-well plates in full media for 24 hours and then serum-starved them (0.5% FBS) for 24 hours before treatment. Cells were exposed to sPLA 2 IIa inhibitor (10-40 mmol/L) or vehicle control in serum-starved media for 24 hours. A time-response experiment using 12-, 24-, and 48-hour time points was used to determine the 24-hour time point chosen for this experiment (data not shown). Cell viability was measured with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay according to manufacturer instructions (Roche Applied Science, Indianapolis, Ind).
Western Blot
Cells were plated on 6-well plates at a density of 3 3 10 6 in full media for 24 hours, then serum-starved (0.5% FBS) for 24 hours, and then treated. Time trials with TNF-a were performed to determine the time of maximal initial increase in phosphorylation of NF-kB and ERK 1/2 in all cell lines. Cells were pretreated with sPLA 2 IIa inhibitor (10-40 mmol/L) for 1 hour, stimulated with TNF-a, then lysed with Laemmli buffer under reducing conditions. In separate experiments, untreated cells were lysed and analyzed for baseline sPLA 2 IIa expression. Proteins were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis techniques and transferred to a nitrocellulose membrane. Membranes were blocked in 5% nonfat milk in phosphate-buffered saline-Tween. Primary antibodies were dissolved in 5% bovine serum albumin in phosphate-buffered saline-Tween. Secondary antibodies were prepared in 5% nonfat milk in phosphate-buffered saline-Tween. The protein of interest was developed using Pierce ECL Chemiluminescent (Thermo Fisher Scientific, Inc, Rockford, Ill). Densitometric analysis was performed using ImageJ Software (National Institutes of Health, Bethesda, Md).
Quantitative Reverse-Transcription Polymerase Chain Reaction (RT-PCR)
Cells were plated on 12-well plates at a density of 1 3 10 6 in full media for 24 hours and serum-starved (0.5% FBS) for 24 hours before lysis and RNA isolation. RNA was prepared using the Qiagen RNeasy Plus Mini Kit according to the manufacturer's protocol (Germantown, Md). Complementary DNA was synthesized using Bio-Rad iScript (Hercules, Calif). RT-PCR was performed using Applied Biosystems Sybr Green Master Mix (Carlsbad, Calif). The primer sequences used are as follows: sPLA 2 IIa (forward): CCC-TCC-TAC-TGT-TGG-CAG-TGA-T; sPLA 2 IIa (reverse): CCT-GTC-GTC-AAC-TTG-ATC-ATT-CTG; GAPDH (forward): CCT-GCA-CCA-CCA-ACT-GCT-TAG; GAPDH (reverse): TGA-GTC-CTT-CCA-CGA-TAC-CAA. Denaturation (95 C, 15 seconds), annealing (52 C, 30 seconds), and elongation (72 C, 30 seconds) steps were repeated for 40 cycles, flanked by a 10-minute denaturation and 5-minute elongation step. Data were analyzed by the DDCt method. 10 
Lung Tumor Tissue Collection
Human lung tissue and corresponding clinical data were collected under a tissue banking protocol approved by the University of Colorado Institutional Review Board. Informed consent was obtained from each participant. The stage reported is the pathologic stage after surgical resection according to American Joint Committee on Cancer guidelines. Tumor samples and normal-appearing tissue from resected lobes were collected in RNALater (Qiagen). Complementary DNA and subsequent quantitative RT-PCR were prepared as described above.
Statistical Analysis
All data distributions were inspected before statistical analysis. The Student t test was performed for 2-group comparisons, and the analysis of variance test was performed when comparing 3 or more groups. No multiple comparison was conducted. StatView version 5.0 was used for all statistical analysis (SAS Institute, Inc, Cary, NC).
Abbreviations and Acronyms
EGFR ¼ epidermal growth factor receptor ERK Group IIa sPLA 2 expression varies in K-ras mutant lung cancer cells. SW1573 and H2009 express more sPLA 2 IIa messenger RNA (mRNA) compared with H358 and A549 cells (Figure 1, A) . Protein analysis by Western blot and immunofluorescence corroborate this finding (Figure 1 , B and C).
Cell Survival in K-ras Mutant Lung Cancer Cells
Depends on sPLA 2 IIa Expression sPLA 2 IIa inhibition led to concentration-dependent apoptosis and cell death in all K-ras mutant lung cancer cells ( Figure 2 ). Cells with higher baseline sPLA 2 IIa were more susceptible to cell death with sPLA 2 IIa inhibition. Early apoptosis detected by annexin V staining after 8 hours of sPLA 2 IIa inhibition was increased in SW1573 and H2009 cells compared with H358 and A549 cells (Figure 2, A) . The MTT assay confirmed concentrationdependent cell death after 24 hours of sPLA 2 IIa inhibition, again with increased vulnerability in cells with higher sPLA 2 IIa expression ( Figure 2, B) .
sPLA 2 IIa Inhibition in K-ras Mutants Decreases NF-kB Phosphorylation
Previous work has demonstrated that sPLA 2 IIa inhibition-associated apoptosis is related predominantly to decreased NF-kB activity. 4 We confirmed that NF-kB phosphorylation is decreased with sPLA 2 IIa inhibition in FIGURE 1. K-ras mutant lung cancer cell lines analyzed for baseline group IIa secretory phospholipase A 2 (sPLA 2 IIa) expression. Expression varies with SW1573 and H2009 cells expressing more sPLA 2 IIa compared with H358 and A549 cells. Messenger RNA (mRNA) was evaluated by quantitative reversetranscription polymerase chain reaction (RT-PCR), mean AE SEM, *P<.05, n ¼ 5, run in triplicate (A). sPLA 2 IIa protein expression was evaluated by Western blot. Graph of densitometry, mean AE SEM, **P <.005, n ¼ 4 (B). Immunofluorescence for sPLA 2 IIa was used for additional protein, n ¼ 3 run in duplicate, sPLA 2 IIa ¼ red, cell membrane ¼ green, nuclei ¼ blue (C). IgG, Immunoglobulin G; GAPDH, glyceraldehyde 3-phosphate dehydrogenase. all K-ras mutant cells, whereas ERK 1/2 phosphorylation increases in 3 cell lines but decreases in A549 cells (Figure 3 ). H2009 and H358 cells have a more modest decrease in NF-kB compared with SW1573 and A549 cells. H2009 and H358 cells are both p53 mutant.
Human Lung Tumors Express sPLA 2 IIa
Fifteen lung tumors were examined for sPLA 2 IIa mRNA expression. One metastatic colon adenocarcinoma and 1 invasive esophageal adenocarcinoma were included in analysis for comparison. Lung tumors express detectable levels of sPLA 2 IIa mRNA (Figure 4 ). Although squamous and K-ras mutant tumors are less common in our cohort, there is a trend toward increased expression of sPLA 2 IIa in squamous tumors. In K-ras mutant tumors there is evidence of increased sPLA 2 IIa expression with increasing stage. Both large cell neuroendocrine tumors express low levels of sPLA 2 IIa.
DISCUSSION
This is the first study to specifically explore the role of sPLA 2 IIa in K-ras mutant lung cancer. Consistent with our hypothesis, sPLA 2 IIa is a cytotoxic target in K-ras mutant lung cancer cells. Our finding that in vitro sensitivity to sPLA 2 IIa inhibition correlates with baseline sPLA 2 IIa expression, regardless of p53 mutation status, suggests that sPLA 2 IIa expression may predict response to sPLA 2 IIa inhibition. Analysis of sPLA 2 IIa expression in human lung tumors revealed some trends that we did not anticipate. Expression increases with cancer stage in K-ras mutant tumors, but it does not necessarily increase with stage of non-small cell lung cancers overall. In addition, we found a trend of relatively high expression in squamous cell tumors, another subset of lung tumors that presently lacks targeted therapy. These findings are intriguing. Not only do they suggest that sPLA 2 IIa may be a more sensitive biomarker for a subset of tumors, but small molecule inhibitors to sPLA 2 IIa have already been trialed for inflammatory disease, 11 thus underscoring the possibility for rapid translational study in lung cancer.
Although with mutant p53 had a less robust decrease in NF-kB activity. Other investigators have demonstrated a relationship between mutant p53 and increased baseline NF-kB activity. 12, 13 Our data corroborate this observation and further advance our understanding of the relationship between sPLA 2 IIa and NF-kB by demonstrating that sPLA 2 IIa inhibition has a more modest effect on the activity of NF-kB in cancer cells where baseline activity is high. Additional studies are needed to determine whether this observation has implications for the effect of sPLA 2 IIa inhibition on downstream NF-kB targets such as metastasis-associated adhesion molecules and expression of inducible growth factors. 5, [14] [15] [16] [17] An interesting and unexpected finding from our tumor analysis was that sPLA 2 IIa expression was increased in squamous tumors. Kupert and associates 3 recently published strong sPLA 2 IIa protein staining in non-small cell lung tumor cores compared with normal lung tissue, including 100% of squamous cell tumor cores, although they did not quantify differences between histologic subtypes. 3 This trend requires focused investigation of more squamous tumors inasmuch as there are currently no targeted therapies for this subset of non-small cell lung cancers. Furthermore, there is potential to examine the relationship between specific genetic alterations in squamous tumors and the tumor promoting activity of sPLA 2 IIa. 18 FIGURE 3. Group IIa secretory phospholipase A 2 (sPLA 2 IIa) inhibition attenuates nuclear factor kappa-b (NF-kB) activity in all cell lines, with a variable effect on extracellular signal-regulated kinase (ERK) 1/2 activity. NF-kB attenuation does not correlate with sPLA 2 IIa expression level. Both H2009 and H358 (white bar graphs) are mutant p53 and demonstrate a more modest decrease in NF-kB activity (vc, vehicle control). Representative Western blots with corresponding densitometry, mean AE SEM, *P <.05, **P <.01, #P <.001, n ¼ 3-5.
The pathways most frequently implicated in phospholipaserelated tumor growth are predominantly inflammatory, including NF-kB and the arachidonic acid-eicosanoid pathway. 14, 19, 20 Mechanistic investigation of how sPLA 2 IIa effects production of tumor-promoting eicosanoids, including its interactions with other phospholipase enzymes, is ongoing. In addition, sPLA 2 IIa is a secreted molecule with potential autocrine and paracrine signaling capability. 21 Ongoing studies aim to clarify the effect of sPLA 2 IIa inhibition on sPLA 2 IIa production and secretion with implications for understanding the role of sPLA 2 IIa in the tumor microenvironment to promote tumor progression and metastasis.
A limitation of this study is the use of a single small molecule inhibitor. We have previously presented comparable results with RNA interference of sPLA 2 IIa, resulting in decreased tumor growth in an animal model. 4 In addition, our tumor tissue analysis was limited owing to small sample size. Furthermore, we were only able to analyze mRNA secondary to the limited amount of tissue available to us. The analysis of RNA and protein in the lung cancer cell FIGURE 4 . Human lung tumors express group IIa secretory phospholipase A 2 (sPLA 2 IIa). Primary lung tumors (n ¼ 15), invasive esophageal adenocarcinoma (n ¼ 1), lung metastasis from colon adenocarcinoma primary (n ¼ 1). K-ras mutant adenocarcinomas (gray) express increasing levels of sPLA 2 IIa with increasing stage. Squamous cell carcinomas (black) express higher levels of sPLA 2 IIa. Samples that did not include K-ras, ALK, or epidermal growth factor receptor (EGFR) mutant status indicate patients that did not consent to mutation analysis. Messenger RNA evaluated by quantitative reversetranscription polymerase chain reaction (RT-PCR), samples run in triplicate. LCNEC, Large cell neuroendocrine carcinoma; mut, mutant; wt, wild-type; s/p, status post; XRT, radiation therapy. lines mostly demonstrates a parallel relationship between sPLA 2 IIa mRNA transcript and sPLA 2 IIa protein expression. Future studies will need to include an analysis of protein expression of sPLA 2 IIa in tumors.
In summary, we have outlined the potential of sPLA 2 IIa as a global target for lung cancer therapy-sPLA 2 inhibition is cytotoxic and potency correlates with baseline sPLA 2 expression. Examination of human lung tumors suggests sPLA 2 IIa has particular relevance for K-ras mutant and squamous cell tumors, 2 lung cancer subsets that presently pose therapeutic challenges. These data contribute to growing evidence of a role for sPLA 2 IIa in lung cancer that deserves further translational investigation.
